FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010235078> ?p ?o ?g. }

• W3010235078 endingPage "1207" @default.
• W3010235078 startingPage "1195" @default.
• W3010235078 abstract "BackgroundOptimal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor to morbidity and mortality among people with HIV, have not been systematically evaluated in low-income and middle-income countries, where the disease is most common. In this study, we aimed to investigate optimal treatment strategies for advanced stage disease in areas of high prevalence and limited resources.MethodsIn this open-label, non-inferiority trial, we enrolled people with HIV and advanced stage AIDS-associated Kaposi sarcoma attending 11 AIDS Clinical Trials Group sites in Brazil, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Eligible participants were randomly assigned (1:1:1) with a centralised computer system to receive either intravenous bleomycin and vincristine or oral etoposide (the investigational arms), or intravenous paclitaxel (the control arm), together with antiretroviral therapy (ART; combined efavirenz, tenofovir disoproxil fumarate, and emtricitabine). The primary outcome was progression-free survival (PFS) at week 48, using a 15% non-inferiority margin to compare the investigational groups against the active control group. Safety was assessed in all eligible treated study participants. The study was registered with ClinicalTrials.gov, NCT01435018.Findings334 participants were enrolled between Oct 1, 2013, and March 8, 2018, when the study was closed early due to inferiority of the bleomycin and vincristine plus ART arm, as per the recommendations of the Data and Safety Monitoring Board (DSMB). The etoposide plus ART arm also closed due to inferiority in March, 2016, following a DSMB recommendation. Week-48 PFS rates were higher in the paclitaxel plus ART arm than in both investigational arms. The absolute differences in PFS were −30% (95% CI −52 to −8) for the comparison of paclitaxel plus ART (week 48 PFS 50%, 32 to 67; n=59) and etoposide plus ART (20%, 6 to 33; n=59), and −20% (−33% to −7%) for the comparison of paclitaxel plus ART (64%, 55 to 73; n=138) and bleomycin and vincristine plus ART (44%, 35 to 53; n=132). Both CIs overlapped the non-inferiority margin. The most common adverse events, in 329 eligible participants who began treatment, were neutropenia (48 [15%]), low serum albumin (33 [10%]), weight loss (29 [9%]), and anaemia (28 [9%]), occurring at similar frequency across treatment arms.InterpretationNon-inferiority of either investigational intervention was not shown, with paclitaxel plus ART showing superiority to both oral etoposide plus ART and bleomycin and vincristine plus ART, supporting its use in treating advanced AIDS-associated Kaposi sarcoma in resource-limited settings.FundingUS National Institute of Allergy and Infectious Diseases and National Cancer Institute, National Institutes of Health." @default.
• W3010235078 created "2020-03-13" @default.
• W3010235078 creator A5002926065 @default.
• W3010235078 creator A5004531613 @default.
• W3010235078 creator A5007161511 @default.
• W3010235078 creator A5009781874 @default.
• W3010235078 creator A5014238491 @default.
• W3010235078 creator A5014418781 @default.
• W3010235078 creator A5015341987 @default.
• W3010235078 creator A5019322508 @default.
• W3010235078 creator A5021211542 @default.
• W3010235078 creator A5022404707 @default.
• W3010235078 creator A5023067810 @default.
• W3010235078 creator A5025155321 @default.
• W3010235078 creator A5025984594 @default.
• W3010235078 creator A5027304381 @default.
• W3010235078 creator A5027328268 @default.
• W3010235078 creator A5027758448 @default.
• W3010235078 creator A5027847898 @default.
• W3010235078 creator A5029562926 @default.
• W3010235078 creator A5030163665 @default.
• W3010235078 creator A5031091506 @default.
• W3010235078 creator A5031562610 @default.
• W3010235078 creator A5032891400 @default.
• W3010235078 creator A5035764371 @default.
• W3010235078 creator A5037474650 @default.
• W3010235078 creator A5038527599 @default.
• W3010235078 creator A5041594897 @default.
• W3010235078 creator A5041987464 @default.
• W3010235078 creator A5042084556 @default.
• W3010235078 creator A5042563758 @default.
• W3010235078 creator A5045885668 @default.
• W3010235078 creator A5049620208 @default.
• W3010235078 creator A5049948120 @default.
• W3010235078 creator A5050874781 @default.
• W3010235078 creator A5050919683 @default.
• W3010235078 creator A5052872878 @default.
• W3010235078 creator A5054341206 @default.
• W3010235078 creator A5056372296 @default.
• W3010235078 creator A5056409417 @default.
• W3010235078 creator A5057521107 @default.
• W3010235078 creator A5057665943 @default.
• W3010235078 creator A5058900593 @default.
• W3010235078 creator A5059154513 @default.
• W3010235078 creator A5064007142 @default.
• W3010235078 creator A5071495374 @default.
• W3010235078 creator A5071598180 @default.
• W3010235078 creator A5071825512 @default.
• W3010235078 creator A5075060991 @default.
• W3010235078 creator A5078258585 @default.
• W3010235078 creator A5079853718 @default.
• W3010235078 creator A5081269417 @default.
• W3010235078 creator A5081512574 @default.
• W3010235078 creator A5082967785 @default.
• W3010235078 creator A5083035273 @default.
• W3010235078 creator A5083965763 @default.
• W3010235078 creator A5084454436 @default.
• W3010235078 creator A5086723848 @default.
• W3010235078 creator A5089384391 @default.
• W3010235078 creator A5090553690 @default.
• W3010235078 creator A5091277501 @default.
• W3010235078 creator A5091320018 @default.
• W3010235078 creator A5000494490 @default.
• W3010235078 creator A5046868262 @default.
• W3010235078 creator A5049503592 @default.
• W3010235078 creator A5073841828 @default.
• W3010235078 creator A5087288404 @default.
• W3010235078 creator A5090746859 @default.
• W3010235078 date "2020-04-01" @default.
• W3010235078 modified "2023-10-18" @default.
• W3010235078 title "Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial" @default.
• W3010235078 cites W1565730670 @default.
• W3010235078 cites W1782134579 @default.
• W3010235078 cites W1838533005 @default.
• W3010235078 cites W1840531404 @default.
• W3010235078 cites W1918322381 @default.
• W3010235078 cites W1962046702 @default.
• W3010235078 cites W1967312569 @default.
• W3010235078 cites W2008835015 @default.
• W3010235078 cites W2012352057 @default.
• W3010235078 cites W2018989052 @default.
• W3010235078 cites W2046775421 @default.
• W3010235078 cites W2059707463 @default.
• W3010235078 cites W2060499368 @default.
• W3010235078 cites W2075419290 @default.
• W3010235078 cites W2081963196 @default.
• W3010235078 cites W2107248017 @default.
• W3010235078 cites W2138435494 @default.
• W3010235078 cites W2165837635 @default.
• W3010235078 cites W2231243009 @default.
• W3010235078 cites W2261620898 @default.
• W3010235078 cites W2615529999 @default.
• W3010235078 cites W2769201756 @default.
• W3010235078 cites W2775729452 @default.
• W3010235078 cites W2794857767 @default.
• W3010235078 cites W2882810607 @default.
• W3010235078 cites W2902070389 @default.
• W3010235078 cites W2916496948 @default.

• next